

Helmut U Klein

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2886553/helmut-u-klein-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

58
papers

13,809
citations

24
h-index

71
g-index

71
ext. papers

16,004
ext. citations

7.7
avg, IF

5.35
L-index

#	Paper	IF	Citations
58	Advances in Our Clinical Understanding of Autonomic Regulation Therapy Using Vagal Nerve Stimulation in Patients Living With Heart Failure.. <i>Frontiers in Physiology</i> , 2022 , 13, 857538	4.6	1
57	Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry. <i>Clinical Research in Cardiology</i> , 2021 , 110, 102-113	6.1	6
56	Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score. <i>European Heart Journal</i> , 2021 , 42, 1676-1684	9.5	16
55	Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEM-HF, INOVATE-HF, and NECTAR-HF. <i>ESC Heart Failure</i> , 2020 , 7, 75-83	3.7	23
54	Death with an implantable cardioverter-defibrillator: a MADIT-II substudy. <i>Europace</i> , 2019 , 21, 1843-1850	9.9	5
53	Considering the Need to Expand the Indications for Wearable Defibrillator Therapy. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2019 , 10, 3751-3760	1.1	
52	Impact of Autonomic Regulation Therapy in Patients with Heart Failure: ANTHEM-HF rEF Pivotal Study Design. <i>Circulation: Heart Failure</i> , 2019 , 12, e005879	7.6	21
51	Comparison of Long-Term Survival Benefits With Cardiac Resynchronization Therapy in Patients With Mild Heart Failure With Versus Without Diabetes Mellitus (from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy [MADIT-CRT]). <i>American Journal of Cardiology</i> , 2018 , 121, 1567-1574	3	3
50	Right ventricular lead location, right-left ventricular lead interaction, and long-term outcomes in cardiac resynchronization therapy patients. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018 , 52, 185-194	2.4	3
49	One-year follow-up of the prospective registry of patients using the wearable defibrillator (WEARIT-II Registry). <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018 , 41, 1307-1313	1.6	9
48	Arthur Jay Moss MD PhD: The cardiology world has again lost one of its most respected and worldwide-honoured scholars and experienced clinician. Born 21 June 1931, Professor of Medicine and Cardiology at Rochester University Medical Center, Rochester, NY, Arthur passed away on 14 February 2018 at the age of 86. <i>European Heart Journal</i> , 2018 , 39, 1672-1674	9.5	
47	Extended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death. <i>Europace</i> , 2018 , 20, f225-f232	3.9	9
46	Left Ventricular Lead Location and Long-Term Outcomes in Cardiac Resynchronization Therapy Patients. <i>JACC: Clinical Electrophysiology</i> , 2018 , 4, 1410-1420	4.6	11
45	Experience with the wearable cardioverter-defibrillator in older patients: Results from the Prospective Registry of Patients Using the Wearable Cardioverter-Defibrillator. <i>Heart Rhythm</i> , 2018 , 15, 1379-1386	6.7	6
44	Safety of the Wearable Cardioverter Defibrillator (WCD) in Patients with Implanted Pacemakers. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2017 , 40, 271-277	1.6	4
43	The impact of body mass index on the wearable cardioverter defibrillator shock efficacy and patient wear time. <i>American Heart Journal</i> , 2017 , 186, 111-117	4.9	2
42	Multicenter Automatic Defibrillator Implantation Trial-Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol. <i>American Heart Journal</i> , 2017 , 189, 158-166	4.9	27

41	Long-term vagal stimulation for heart failure: Eighteen month results from the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) trial. <i>International Journal of Cardiology</i> , 2017 , 244, 229-234	3.2	54
40	The wearable cardioverter-defibrillator: current technology and evolving indications. <i>Europace</i> , 2017 , 19, 335-345	3.9	41
39	Effect of Significant Weight Change on Inappropriate Implantable Cardioverter-Defibrillator Therapy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2017 , 40, 9-16	1.6	4
38	Effect of cardiac resynchronization therapy on the risk of ventricular tachyarrhythmias in patients with chronic kidney disease. <i>Annals of Noninvasive Electrocardiology</i> , 2017 , 22,	1.5	2
37	Rationale and design of the BUDAPEST-CRT Upgrade Study: a prospective, randomized, multicentre clinical trial. <i>Europace</i> , 2017 , 19, 1549-1555	3.9	14
36	Cardiac Resynchronization in Different Age Groups: A MADIT-CRT Long-Term Follow-Up Substudy. <i>Journal of Cardiac Failure</i> , 2016 , 22, 143-9	3.3	5
35	Sustained clinical benefit of cardiac resynchronization therapy in non-LBBB patients with prolonged PR-interval: MADIT-CRT long-term follow-up. <i>Clinical Research in Cardiology</i> , 2016 , 105, 944-952	6.1	32
34	Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure. <i>Heart</i> , 2016 , 102, 1742-1749	5.1	21
33	Letter to the Editor- Prognostic implication of baseline PR interval in patients undergoing cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2016 , 13, 1573	6.7	
32	No Utility of the Wearable Cardioverter-Defibrillator in Patients With Nonischemic Cardiomyopathy?. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2807	15.1	
31	Long-Term Outcomes With Cardiac Resynchronization Therapy in Patients With Mild Heart Failure With Moderate Renal Dysfunction. <i>Circulation: Heart Failure</i> , 2015 , 8, 725-32	7.6	15
30	Sex Differences in Long-Term Outcomes With Cardiac Resynchronization Therapy in Mild Heart Failure Patients With Left Bundle Branch Block. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	25
29	Michel Mirowski and the beginning of a new era of fighting sudden arrhythmic death. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2015 , 26, 61-9	0.8	0
28	Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry). <i>Circulation</i> , 2015 , 132, 1613-9	16.7	148
27	Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. <i>European Heart Journal</i> , 2015 , 36, 425-33	9.5	208
26	Apical vs. non-apical right ventricular pacing in cardiac resynchronization therapy: a meta-analysis. <i>Europace</i> , 2015 , 17, 1259-66	3.9	32
25	Time-dependent risk reduction of ventricular tachyarrhythmias in cardiac resynchronization therapy patients: a MADIT-RIT sub-study. <i>Europace</i> , 2015 , 17, 1085-91	3.9	14
24	The effect of ICD programming on inappropriate and appropriate ICD Therapies in ischemic and nonischemic cardiomyopathy: the MADIT-RIT trial. <i>Journal of Cardiovascular Electrophysiology</i> , 2015 , 26, 424-433	2.7	21

23	Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014 , 7, 785-92	6.4	85
22	Cardiac resynchronization therapy is associated with reductions in left atrial volume and inappropriate implantable cardioverter-defibrillator therapy in MADIT-CRT. <i>Heart Rhythm</i> , 2014 , 11, 1001-7	6.7	4
21	Response to letter regarding, "PR interval identifies clinical response in patients with non-left bundle branch block: a multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy sub-study" by Kutiyifa et al. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014 , 7, 1280	6.4	1
20	Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator. <i>European Journal of Heart Failure</i> , 2014 , 16, 1331-6	12.3	93
19	Rationale and study design of the NEuroCardiac TherApy foR Heart Failure Study: NECTAR-HF. <i>European Journal of Heart Failure</i> , 2014 , 16, 692-9	12.3	42
18	A metric for evaluating the cardiac response to resynchronization therapy. <i>American Journal of Cardiology</i> , 2014 , 113, 1371-7	3	9
17	Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator. <i>European Heart Journal</i> , 2013 , 34, 2230-42	9.5	84
16	Reduction in inappropriate therapy and mortality through ICD programming. <i>New England Journal of Medicine</i> , 2012 , 367, 2275-83	59.2	900
15	Preventive cardiac resynchronisation therapy. <i>Heart</i> , 2012 , 98, 508-15	5.1	
14	Wearable defibrillator in congenital structural heart disease and inherited arrhythmias. <i>American Journal of Cardiology</i> , 2011 , 108, 1632-8	3	28
13	Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. <i>European Heart Journal</i> , 2011 , 32, 847-55	9.5	354
12	Bridging a temporary high risk of sudden arrhythmic death. Experience with the wearable cardioverter defibrillator (WCD). <i>PACE - Pacing and Clinical Electrophysiology</i> , 2010 , 33, 353-67	1.6	101
11	Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2010 , 12, 431-42	2.1	0
10	Vagus nerve stimulation: A new approach to reduce heart failure. <i>Cardiology Journal</i> , 2010 , 17, 638-44	1.4	41
9	Implantable defibrillators: 30 years of history 2010 , 11, 48S-52S		3
8	Cardiac-resynchronization therapy for the prevention of heart-failure events. <i>New England Journal of Medicine</i> , 2009 , 361, 1329-38	59.2	2105
7	The Wearable Cardioverter Defibrillator-Bridge to the Implantable Defibrillator. <i>Cardiac Electrophysiology Clinics</i> , 2009 , 1, 129-146	1.4	
6	Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 1357-65	15.1	612

5	Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BIROAD. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2004 , 27, 4-9	1.6	160
4	Clinical efficacy of a wearable defibrillator in acutely terminating episodes of ventricular fibrillation using biphasic shocks. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2003 , 26, 2016-22	1.6	55
3	Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. <i>New England Journal of Medicine</i> , 2002 , 346, 877-83	59.2	5079
2	Clinical efficacy of the wearable cardioverter-defibrillator in acutely terminating episodes of ventricular fibrillation. <i>American Journal of Cardiology</i> , 1998 , 81, 1253-6	3	68
1	Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. <i>New England Journal of Medicine</i> , 1996 , 335, 1933-40	59.2	3200